Biomarkers /

CDH2

Back to Biomarkers List
Associated Diseases

Overview

Location [1]
18q12.1
Protein [2]
Cadherin-2
Synonyms [1]
ARVD14, CDHN, ACOGS, NCAD, CD325, CDw325

CDH2 is altered in 0.09% of all cancers with high grade ovarian serous adenocarcinoma, colorectal adenocarcinoma, anaplastic astrocytoma, bladder urothelial carcinoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].

CDH2 GENIE Cases - Top Diseases

The most common alterations in CDH2 are CDH2 N500S (0.28%), CDH2 A464E (3.85%), CDH2 A521V (0.20%), CDH2 D377N (0.20%), and CDH2 D750N (0.22%) [3].

CDH2 GENIE Cases - Top Alterations

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.